2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3721 Single-cell glycomic profiling identifies glycosylation remodeling and therapeutic vulnerability in myeloproliferative neoplasms

Fan He, PhD, Varun Ramesh2, Shuyang Lin, BA3, Roderick Lin4, Tim Kong, MD, PhD5, Alexander B. Kim6, Yanbo Yu7, Molly Brakhane, PhD8, Christopher Letson, PhD, BS9, Matias Grodzielski10, Maggie Cox11, Xuemei Zhu12, Mary Fulbright13, Diane Bender14, Stephen Sykes, PhD15, Jorge Di Paola, MD16, Stephen Oh, MD, PhD17
1 Washington University School of Medicine, Saint Louis, United States
2 Washington University School of Medicine, Saint Louis, United States
3 Washington University School of Medicine, Saint Louis, United States
4 Washington University School of Medicine, Saint Louis, United States
5 Washington University School of Medicine, Saint Louis, United States
6 Washington University School of Medicine, Saint Louis, United States
7 Washington University School of Medicine, Saint Louis, United States
8 Washington University School of Medicine, Saint Louis, United States
9 Washington University School of Medicine, Saint Louis, United States
10 Washington University School of Medicine, Saint Louis, United States
11 Washington University School of Medicine, Saint Louis, United States
12 Washington University School of Medicine, Saint Louis, United States
13 Washington University School of Medicine, Saint Louis, United States
14 Washington University School of Medicine, Saint Louis, United States
15 Washington University School of Medicine, Saint Louis, United States
16 Washington University School of Medicine, Saint Louis, United States
17 Washington University School of Medicine, Saint Louis, United States
Essential thrombocythemia (ET) and myelofibrosis (MF) represent a clinical continuum, with a subset of ET patients progressing to more aggressive, fibrotic MF. Although driver mutations (JAK2, CALR, and MPL) are well characterized, the molecular mechanisms driving disease progression remain poorly understood. Aberrant glycosylation is a recognized hallmark of malignant transformation, yet its role in myeloproliferative neoplasms (MPNs) remains largely unexplored. We previously demonstrated that galectin-1 regulates myeloid TLR4 signaling, establishing glycan-lectin interactions as functionally important in MPN biology (He et al, Blood 2026). However, no single-cell platform exists to comprehensively profile cellular glycosylation, leaving it unclear whether glycosylation contributes to MPN pathogenesis.

To address this, we developed a Lectin-CyTOF platform by conjugating ten glycan-binding lectins to heavy metal isotopes for detection by cytometry by time-of-flight (CyTOF), enabling single-cell profiling of major glycan classes, including fucosylation, sialylation, mannosylation, terminal galactose, and LacNAc, the canonical galectin-1 ligand. Lectin specificity was validated using enzymatic and pharmacologic glycan remodeling approaches that selectively altered the corresponding glycan epitopes, confirming accurate glycan detection. Applying this platform to primary MPN samples revealed two major glycomic features. First, myeloid cells exhibited substantially higher glycan abundance than lymphoid cells, a lineage-specific pattern that was independently recapitulated by higher glycan signals in THP-1 myeloid cells compared with Molt3 T and Raji B cell lines. Second, glycan remodeling progressively increased with disease severity, with MF samples exhibiting significantly higher fucosylation, mannosylation, and LacNAc expression than ET samples across both leukocyte and platelet compartments.

To determine the functional relevance of these glycosylation changes, we pharmacologically inhibited glycosylation using 2-deoxyglucose (2-DG). Western blot analysis demonstrated reduced glycosylation of LAMP1, a highly-glycosylated protein, and TLR4, which was rescued by mannose supplementation, confirming effective modulation of glycosylation. Functionally, 2-DG potently inhibited the viability of multiple myeloid cell lines, with MPLW515L mutant cells exhibiting significantly greater sensitivity than parental Ba/F3 and wild-type MPL-expressing cells, suggesting increased dependence on glycosylation. Consistent with these findings, 2-DG treatment significantly attenuated splenomegaly and myelopoiesis in a JAK2V617F murine MPN model.

Together, these findings establish Lectin-CyTOF as a robust platform for single-cell glycan profiling, reveal lineage-dependent glycan abundance and progressive glycan remodeling during MPN evolution, and identify glycosylation as a potential therapeutic vulnerability in MPN.
Fan He, PhD: No relevant conflicts of interest to declare.